[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Ropinirole.]
[L01AD04, streptozocin, The metabolism of Ropinirole can be increased when combined with Streptozocin.]
[M03AB01, succinylcholine, Succinylcholine may increase the sedative activities of Ropinirole.]
[N05AL01, sulpiride, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Sulpiride.]
[N03AX03, sulthiame, Sulthiame may increase the sedative activities of Ropinirole.]
[N05CD07, temazepam, Temazepam may increase the sedative activities of Ropinirole.]
[S01HA03, tetracaine, Tetracaine may increase the sedative activities of Ropinirole.]
[N05AE05, lurasidone, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the sedative activities of Ropinirole.]
[N04BC07, apomorphine, Apomorphine may increase the sedative activities of Ropinirole.]
[L04AX02, thalidomide, Thalidomide may increase the sedative activities of Ropinirole.]
[P02CA02, thiabendazole, The risk or severity of adverse effects can be increased when Thiabendazole is combined with Ropinirole.]
[R06AD03, thiethylperazine, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Thiethylperazine.]
[N05CA19, thiopental, Thiopental may increase the sedative activities of Ropinirole.]
[N05AB08, thioproperazine, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Thioproperazine.]
[N05AC02, thioridazine, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Thioridazine.]
[N05AF04, thiothixene, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Thiothixene.]
[N05AL03, tiapride, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Tiapride.]
[B01AC05, ticlopidine, The risk or severity of adverse effects can be increased when Ticlopidine is combined with Ropinirole.]
[N02AX01, tilidine, Tilidine may increase the sedative activities of Ropinirole.]
[S01ED01, timolol, The risk or severity of adverse effects can be increased when Ropinirole is combined with Timolol.]
[M02AX02, tolazoline, The risk or severity of adverse effects can be increased when Ropinirole is combined with Tolazoline.]
[M03BX04, tolperisone, Tolperisone may increase the sedative activities of Ropinirole.]
[N02AX02, tramadol, Tramadol may increase the sedative activities of Ropinirole.]
[N06AF04, tranylcypromine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ropinirole.]
[N06AX05, trazodone, Trazodone may increase the sedative activities of Ropinirole.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Ropinirole is combined with Tretinoin.]
[C03DB02, triamterene, The risk or severity of adverse effects can be increased when Ropinirole is combined with Triamterene.]
[N05CD05, triazolam, Triazolam may increase the sedative activities of Ropinirole.]
[C03AA06, trichlormethiazide, Ropinirole may increase the hypotensive activities of Trichlormethiazide.]
[N05AB06, trifluoperazine, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Trifluoperazine.]
[N05AD02, trifluperidol, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Trifluperidol.]
[N05AA05, triflupromazine, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Triflupromazine.]
[R06AD01, trimeprazine, Alimemazine may increase the sedative activities of Ropinirole.]
[N03AC02, trimethadione, Trimethadione may increase the sedative activities of Ropinirole.]
[C02BA01, trimethaphan, Ropinirole may increase the hypotensive activities of Trimethaphan.]
[N06AA06, trimipramine, Trimipramine may increase the sedative activities of Ropinirole.]
[R06AX07, triprolidine, Triprolidine may increase the sedative activities of Ropinirole.]
[N06AX24, vilazodone, Vilazodone may increase the sedative activities of Ropinirole.]
[N06AX02, tryptophan, Tryptophan may increase the sedative activities of Ropinirole.]
[C09CA09, azilsartan medoxomil, The risk or severity of adverse effects can be increased when Ropinirole is combined with Azilsartan medoxomil.]
[M03AA02, tubocurarine, Tubocurarine may increase the sedative activities of Ropinirole.]
[L02BX03, abiraterone, The risk or severity of adverse effects can be increased when Abiraterone is combined with Ropinirole.]
[N03AX21, ezogabine, Ezogabine may increase the sedative activities of Ropinirole.]
[C08DA01, verapamil, The risk or severity of adverse effects can be increased when Ropinirole is combined with Verapamil.]
[N06AX09, viloxazine, The risk or severity of adverse effects can be increased when Viloxazine is combined with Ropinirole.]
[C04AX07, vincamine, Ropinirole may increase the hypotensive activities of Vincamine.]
[C03BA10, xipamide, Ropinirole may increase the hypotensive activities of Xipamide.]
[N05AF05, zuclopenthixol, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Zuclopenthixol.]
[N03AX14, levetiracetam, Levetiracetam may increase the sedative activities of Ropinirole.]
[L01EC01, vemurafenib, The serum concentration of Ropinirole can be increased when it is combined with Vemurafenib.]
[A02BC04, rabeprazole, The metabolism of Ropinirole can be increased when combined with Rabeprazole.]
[J01MA13, trovafloxacin, The risk or severity of adverse effects can be increased when Trovafloxacin is combined with Ropinirole.]
[N05AE04, ziprasidone, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Ziprasidone.]
[C07AB03, atenolol, The risk or severity of adverse effects can be increased when Ropinirole is combined with Atenolol.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Ropinirole.]
[M03AC04, atracurium, Atracurium may increase the sedative activities of Ropinirole.]
[G04BE10, avanafil, The risk or severity of hypotension can be increased when Avanafil is combined with Ropinirole.]
[M03BX01, baclofen, Baclofen may increase the sedative activities of Ropinirole.]
[A08AA11, lorcaserin, Lorcaserin may increase the sedative activities of Ropinirole.]
[L04AA31, teriflunomide, The metabolism of Ropinirole can be increased when combined with Teriflunomide.]
[N05CA04, barbital, Barbital may increase the sedative activities of Ropinirole.]
[N04BD02, rasagiline, Rasagiline may increase the sedative activities of Ropinirole.]
[C08CA13, lercanidipine, The risk or severity of adverse effects can be increased when Ropinirole is combined with Lercanidipine.]
[A03FA09, mosapride, Mosapride may increase the sedative activities of Ropinirole.]
[N06DA02, donepezil, Donepezil may increase the sedative activities of Ropinirole.]
[N03AX22, perampanel, Perampanel may increase the sedative activities of Ropinirole.]
[N02CC03, zolmitriptan, Zolmitriptan may increase the sedative activities of Ropinirole.]
[N01AA01, ethyl ether, Diethyl ether may increase the sedative activities of Ropinirole.]
[G04BE03, sildenafil, The risk or severity of hypotension can be increased when Sildenafil is combined with Ropinirole.]
[C03AA01, bendroflumethiazide, The risk or severity of adverse effects can be increased when Ropinirole is combined with Bendroflumethiazide.]
[L04AX06, pomalidomide, Pomalidomide may increase the sedative activities of Ropinirole.]
[N05AD07, benperidol, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Benperidol.]
[A10BK02, canagliflozin, The risk or severity of adverse effects can be increased when Ropinirole is combined with Canagliflozin.]
[J01MA15, gemifloxacin, The risk or severity of adverse effects can be increased when Gemifloxacin is combined with Ropinirole.]
[S01AE07, moxifloxacin, The risk or severity of adverse effects can be increased when Moxifloxacin is combined with Ropinirole.]
[A06AX06, tegaserod, The risk or severity of adverse effects can be increased when Tegaserod is combined with Ropinirole.]
[A10AE05, insulin detemir, The metabolism of Ropinirole can be increased when combined with Insulin detemir.]
[R02AD01, benzocaine, Benzocaine may increase the sedative activities of Ropinirole.]
[N02CC02, naratriptan, Naratriptan may increase the sedative activities of Ropinirole.]
[L01EC02, dabrafenib, The risk or severity of adverse effects can be increased when Dabrafenib is combined with Ropinirole.]
[P03AX06, benzyl alcohol, Benzyl alcohol may increase the sedative activities of Ropinirole.]
[N06AX28, levomilnacipran, Levomilnacipran may increase the sedative activities of Ropinirole.]
[C08EA02, bepridil, The risk or severity of adverse effects can be increased when Ropinirole is combined with Bepridil.]
[C02KX05, riociguat, The risk or severity of adverse effects can be increased when Ropinirole is combined with Riociguat.]
[C02KX04, macitentan, Ropinirole may increase the hypotensive activities of Macitentan.]
[N06AX26, vortioxetine, Vortioxetine may increase the sedative activities of Ropinirole.]
[N03AF04, eslicarbazepine, Eslicarbazepine may increase the sedative activities of Ropinirole.]
[J05AP05, simeprevir, The risk or severity of adverse effects can be increased when Simeprevir is combined with Ropinirole.]
[N03AG04, vigabatrin, Vigabatrin may increase the sedative activities of Ropinirole.]
[A10BK01, dapagliflozin, The risk or severity of adverse effects can be increased when Dapagliflozin is combined with Ropinirole.]
[C07AB04, acebutolol, The risk or severity of adverse effects can be increased when Ropinirole is combined with Acebutolol.]
[N05CH03, tasimelteon, Tasimelteon may increase the sedative activities of Ropinirole.]
[L04AA32, apremilast, The metabolism of Ropinirole can be increased when combined with Apremilast.]
[S01ED02, betaxolol, The risk or severity of adverse effects can be increased when Betaxolol is combined with Ropinirole.]
[C02CC01, bethanidine, Ropinirole may increase the hypotensive activities of Bethanidine.]
[L04AC11, siltuximab, The metabolism of Ropinirole can be increased when combined with Siltuximab.]
[L01XH04, belinostat, The metabolism of Ropinirole can be increased when combined with Belinostat.]
[N01AX05, alfaxalone, Alfaxalone may increase the sedative activities of Ropinirole.]
[A10BK03, empagliflozin, The risk or severity of adverse effects can be increased when Ropinirole is combined with Empagliflozin.]
[N05CM19, suvorexant, Suvorexant may increase the sedative activities of Ropinirole.]
[N05AA04, acepromazine, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Acepromazine.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Pirfenidone is combined with Ropinirole.]
[N06AX11, mirtazapine, Mirtazapine may increase the sedative activities of Ropinirole.]
[L04AC10, secukinumab, The metabolism of Ropinirole can be increased when combined with Secukinumab.]
[N05AX16, brexpiprazole, Brexpiprazole may increase the sedative activities of Ropinirole.]
[G02CX02, flibanserin, Flibanserin may increase the sedative activities of Ropinirole.]
[N05AX15, cariprazine, Cariprazine may increase the sedative activities of Ropinirole.]
[S01EC01, acetazolamide, Acetazolamide may increase the sedative activities of Ropinirole.]
[A10AE06, insulin degludec, The metabolism of Ropinirole can be increased when combined with Insulin degludec.]
[N05AB07, acetophenazine, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Acetophenazine.]
[L01EB04, osimertinib, The serum concentration of Ropinirole can be decreased when it is combined with Osimertinib.]
[B01AC27, selexipag, Ropinirole may increase the hypotensive activities of Selexipag.]
[A03FA05, alizapride, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Alizapride.]
[N05CA05, aprobarbital, Aprobarbital may increase the sedative activities of Ropinirole.]
[N03AX23, brivaracetam, Brivaracetam may increase the sedative activities of Ropinirole.]
[N05BA08, bromazepam, Bromazepam may increase the sedative activities of Ropinirole.]
[N04BC01, bromocriptine, Bromocriptine may increase the sedative activities of Ropinirole.]
[A03AX08, alverine, Alverine may increase the sedative activities of Ropinirole.]
[R06AB01, brompheniramine, Dexbrompheniramine may increase the sedative activities of Ropinirole.]
[N06AA19, amineptin, Amineptine may increase the sedative activities of Ropinirole.]
[C08CA01, amlodipine, The risk or severity of adverse effects can be increased when Ropinirole is combined with Amlodipine.]
[N06BX11, aniracetam, Aniracetam may increase the sedative activities of Ropinirole.]
[A05AA04, obeticholic acid, The risk or severity of adverse effects can be increased when Obeticholic acid is combined with Ropinirole.]
[C03CA02, bumetanide, The risk or severity of adverse effects can be increased when Ropinirole is combined with Bumetanide.]
[N01BB01, bupivacaine, Bupivacaine may increase the sedative activities of Ropinirole.]
[C07AA19, bupranolol, Ropinirole may increase the hypotensive activities of Bupranolol.]
[N07BC01, buprenorphine, Buprenorphine may increase the sedative activities of Ropinirole.]
[N05BE01, buspirone, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Buspirone.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Ropinirole is combined with Arsenic trioxide.]
[M02AA03, clofezone, The metabolism of Ropinirole can be increased when combined with Rabeprazole.]
[N02AF01, butorphanol, Butorphanol may increase the sedative activities of Ropinirole.]
[J01MA09, sparfloxacin, The risk or severity of adverse effects can be increased when Sparfloxacin is combined with Ropinirole.]
[S01GX07, azelastine, Azelastine may increase the sedative activities of Ropinirole.]
[L01XK03, rucaparib, The metabolism of Ropinirole can be increased when combined with Rucaparib.]
[N02BF02, pregabalin, Pregabalin may increase the sedative activities of Ropinirole.]
[N03AX30, beclamide, Beclamide may increase the sedative activities of Ropinirole.]
[N06BC01, caffeine, The risk or severity of adverse effects can be increased when Caffeine is combined with Ropinirole.]
[C09AA07, benazepril, The risk or severity of adverse effects can be increased when Ropinirole is combined with Benazepril.]
[S01HA02, benoxinate, Oxybuprocaine may increase the sedative activities of Ropinirole.]
[J01XX08, linezolid, Linezolid may increase the orthostatic hypotensive activities of Ropinirole.]
[L04AB02, infliximab, The metabolism of Ropinirole can be increased when combined with Infliximab.]
[N04BD03, safinamide, The risk or severity of adverse effects can be increased when Safinamide is combined with Ropinirole.]
[L01XX59, enasidenib, The risk or severity of adverse effects can be increased when Enasidenib is combined with Ropinirole.]
[C07AB07, bisoprolol, The risk or severity of adverse effects can be increased when Ropinirole is combined with Bisoprolol.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Efavirenz is combined with Ropinirole.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Ropinirole is combined with Nesiritide.]
[A03FA04, bromopride, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Bromopride.]
[N05AD06, bromperidol, Bromperidol may increase the sedative activities of Ropinirole.]
[N05CD09, brotizolam, Brotizolam may increase the sedative activities of Ropinirole.]
[N05CA03, butobarbital, Butobarbital may increase the sedative activities of Ropinirole.]
[N06AA15, butriptyline, Butriptyline may increase the sedative activities of Ropinirole.]
[N01BX04, capsaicin, The metabolism of Ropinirole can be increased when combined with Capsaicin.]
[N05CA08, butylvinal, Vinylbital may increase the sedative activities of Ropinirole.]
[C09AA01, captopril, The risk or severity of adverse effects can be increased when Ropinirole is combined with Captopril.]
[N03AF01, carbamazepine, The metabolism of Ropinirole can be increased when combined with Carbamazepine.]
[R06AA08, carbinoxamine, Carbinoxamine may increase the sedative activities of Ropinirole.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Ropinirole.]
[C07AG02, carvedilol, The risk or severity of adverse effects can be increased when Ropinirole is combined with Carvedilol.]
[B02BX09, fostamatinib, The risk or severity of hypotension can be increased when Fostamatinib is combined with Ropinirole.]
[N03AX24, cannabidiol, Cannabidiol may increase the sedative activities of Ropinirole.]
[C07AB08, celiprolol, Ropinirole may increase the hypotensive activities of Celiprolol.]
[N03AX17, stiripentol, The metabolism of Ropinirole can be increased when combined with Stiripentol.]
[S01GX12, cetirizine, Cetirizine may increase the sedative activities of Ropinirole.]
[N05CM04, carbromal, Carbromal may increase the sedative activities of Ropinirole.]
[N01BA04, chloroprocaine, Chloroprocaine may increase the sedative activities of Ropinirole.]
[M03BA02, carisoprodol, Carisoprodol may increase the sedative activities of Ropinirole.]
[L04AA39, emapalumab, The metabolism of Ropinirole can be increased when combined with Emapalumab.]
[C09AA08, cilazapril, The risk or severity of adverse effects can be increased when Ropinirole is combined with Cilazapril.]
[A03FA08, cinitapride, Cinitapride may increase the sedative activities of Ropinirole.]
[P02BX04, triclabendazole, The risk or severity of adverse effects can be increased when Triclabendazole is combined with Ropinirole.]
[N06AX27, esketamine, Esketamine may increase the sedative activities of Ropinirole.]
[N06BA14, solriamfetol, Solriamfetol may increase the sedative activities of Ropinirole.]
[N06AX29, brexanolone, Brexanolone may increase the sedative activities of Ropinirole.]
[A03FA06, clebopride, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Clebopride.]
[N05BA09, clobazam, Clobazam may increase the sedative activities of Ropinirole.]
[N05BA22, cloxazolam, Cloxazolam may increase the sedative activities of Ropinirole.]
[C09CA06, candesartan, Ropinirole may increase the hypotensive activities of Candesartan.]
[L04AB01, etanercept, The metabolism of Ropinirole can be increased when combined with Etanercept.]
[N05AA06, cyamemazine, Cyamemazine may increase the sedative activities of Ropinirole.]
[C03BX03, cicletanine, Ropinirole may increase the hypotensive activities of Cicletanine.]
[M03BX08, cyclobenzaprine, Cyclobenzaprine may increase the sedative activities of Ropinirole.]
[N07XX11, pitolisant, The metabolism of Ropinirole can be increased when combined with Pitolisant.]
[C03AA09, cyclothiazide, Ropinirole may increase the hypotensive activities of Cyclothiazide.]
[G04BE04, yohimbine, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Yohimbine.]
[A10AE03, insulin, regular, pork, The metabolism of Ropinirole can be increased when combined with Insulin pork.]
[N02CC08, lasmiditan, Lasmiditan may increase the sedative activities of Ropinirole.]
[A16AX16, givosiran, The serum concentration of Ropinirole can be increased when it is combined with Givosiran.]
[R06AB06, dexbrompheniramine, Dexbrompheniramine may increase the sedative activities of Ropinirole.]
[N02AX03, dezocine, Dezocine may increase the sedative activities of Ropinirole.]
[N05CM21, lemborexant, Lemborexant may increase the sedative activities of Ropinirole.]
[N05AD10, lumateperone, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Lumateperone.]
[M01AX21, diacetylrhein, The risk or severity of adverse effects can be increased when Diacerein is combined with Ropinirole.]
[S01AE06, gatifloxacin, The risk or severity of adverse effects can be increased when Gatifloxacin is combined with Ropinirole.]
[H02CA02, osilodrostat, The risk or severity of adverse effects can be increased when Osilodrostat is combined with Ropinirole.]
[N02CC07, frovatriptan, Frovatriptan may increase the sedative activities of Ropinirole.]
[N05CC04, dichloralphenazone, Dichloralphenazone may increase the sedative activities of Ropinirole.]
[A07DA04, difenoxin, Difenoxin may increase the sedative activities of Ropinirole.]
[N02AA08, dihydrocodeine, Dihydrocodeine may increase the sedative activities of Ropinirole.]
[N02CC06, eletriptan, Eletriptan may increase the sedative activities of Ropinirole.]
[M01AH02, rofecoxib, The risk or severity of adverse effects can be increased when Rofecoxib is combined with Ropinirole.]
[C08CA16, clevidipine, The risk or severity of adverse effects can be increased when Ropinirole is combined with Clevidipine.]
[N03AG02, dipropylacetamide, Valpromide may increase the sedative activities of Ropinirole.]
[N05BA02, chlordiazepoxide, Chlordiazepoxide may increase the sedative activities of Ropinirole.]
[C02AA06, methoserpidine, Ropinirole may increase the hypotensive activities of Methoserpidine.]
[L01EX17, capmatinib, The risk or severity of adverse effects can be increased when Capmatinib is combined with Ropinirole.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Ropinirole is combined with Opicapone.]
[C01CA14, dopexamine, The risk or severity of adverse effects can be decreased when Ropinirole is combined with Dopexamine.]
[N05CM02, chlormethiazole, Clomethiazole may increase the sedative activities of Ropinirole.]
[M03BB02, chlormezanone, Chlormezanone may increase the sedative activities of Ropinirole.]
[R02AD04, dyclonine, Dyclonine may increase the sedative activities of Ropinirole.]
[C08CA17, levamlodipine, Ropinirole may increase the hypotensive activities of Levamlodipine.]
[N05CD14, remimazolam, Remimazolam may increase the sedative activities of Ropinirole.]
[L04AC19, satralizumab, The serum concentration of Ropinirole can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, Oliceridine may increase the sedative activities of Ropinirole.]
[C03AA04, chlorothiazide, The risk or severity of adverse effects can be increased when Ropinirole is combined with Chlorothiazide.]
[G03CA06, chlorotrianisene, Chlorotrianisene may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AB04, chlorpheniramine, Chlorpheniramine may increase the sedative activities of Ropinirole.]
[N05AA01, chlorpromazine, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Chlorpromazine.]
[N05AF03, chlorprothixene, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Chlorprothixene.]
[C03BA04, chlorthalidone, The risk or severity of adverse effects can be increased when Ropinirole is combined with Chlorthalidone.]
[M03BB03, chlorzoxazone, Chlorzoxazone may increase the sedative activities of Ropinirole.]
[N05BX03, etifoxine, Etifoxine may increase the sedative activities of Ropinirole.]
[N06BX18, vinpocetine, Vinpocetine may increase the sedative activities of Ropinirole.]
[N05BA18, ethyl loflazepate, Ethyl loflazepate may increase the sedative activities of Ropinirole.]
[P03AX07, abametapir, The serum concentration of Ropinirole can be increased when it is combined with Abametapir.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Ropinirole is combined with Vericiguat.]
[V03AF12, trilaciclib, The metabolism of Ropinirole can be increased when combined with Trilaciclib.]
[M03BA05, febarbamate, Febarbamate may increase the sedative activities of Ropinirole.]
[N03AX10, felbamate, Felbamate may increase the sedative activities of Ropinirole.]
[C01CA19, fenoldopam, The risk or severity of adverse effects can be decreased when Ropinirole is combined with Fenoldopam.]
[J01MB07, flumequine, The risk or severity of adverse effects can be increased when Flumequine is combined with Ropinirole.]
[A10AF01, insulin, regular, human, The metabolism of Ropinirole can be increased when combined with Insulin human.]
[N01AB05, trichloroethylene, Trichloroethylene may increase the sedative activities of Ropinirole.]
[L03AB10, peginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Ropinirole.]
[H04AA02, dasiglucagon, Ropinirole may increase the hypotensive activities of Dasiglucagon.]
[A02BA01, cimetidine, The risk or severity of adverse effects can be increased when Cimetidine is combined with Ropinirole.]
[N02BF01, gabapentin, Gabapentin may increase the sedative activities of Ropinirole.]
[J01MB06, cinoxacin, The risk or severity of adverse effects can be increased when Cinoxacin is combined with Ropinirole.]
[S03AA07, ciprofloxacin, The risk or severity of adverse effects can be increased when Ciprofloxacin is combined with Ropinirole.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Citalopram is combined with Ropinirole.]
[H01AC07, somapacitan, The metabolism of Ropinirole can be increased when combined with Somapacitan.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Fexinidazole is combined with Ropinirole.]
[H01AC09, lonapegsomatropin, The metabolism of Ropinirole can be increased when combined with Lonapegsomatropin.]
[R06AA04, clemastine, Clemastine may increase the sedative activities of Ropinirole.]
[N06AX25, St. John's wort extract, St. John's Wort may increase the sedative activities of Ropinirole.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Ropeginterferon alfa-2b is combined with Ropinirole.]
[N01BB10, levobupivacaine, Levobupivacaine may increase the sedative activities of Ropinirole.]
[L01EJ03, pacritinib, The metabolism of Ropinirole can be decreased when combined with Pacritinib.]
[N06AA04, clomipramine, Clomipramine may increase the sedative activities of Ropinirole.]
[N03AE01, clonazepam, Clonazepam may increase the sedative activities of Ropinirole.]
[S01EA04, clonidine, Clonidine may increase the sedative activities of Ropinirole.]
[N05AH06, clothiapine, Clothiapine may increase the sedative activities of Ropinirole.]
[N05BA21, clotiazepam, Clotiazepam may increase the sedative activities of Ropinirole.]
[A04AA01, ondansetron, Ondansetron may increase the sedative activities of Ropinirole.]
[A04AA02, granisetron, Granisetron may increase the sedative activities of Ropinirole.]
[N05AH02, clozapine, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Clozapine.]
[N05BA13, halazepam, Halazepam may increase the sedative activities of Ropinirole.]
[H01AC08, somatrogon, The metabolism of Ropinirole can be increased when combined with Somatrogon.]
[C02KB01, metyrosine, Ropinirole may increase the hypotensive activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Ropinirole can be increased when combined with Bimekizumab.]
[R05DA04, codeine, Codeine may increase the sedative activities of Ropinirole.]
[M03AC05, hexafluorenium, Hexafluronium may increase the sedative activities of Ropinirole.]
[L04AA13, leflunomide, The serum concentration of Ropinirole can be decreased when it is combined with Leflunomide.]
[N01AB07, desflurane, Desflurane may increase the sedative activities of Ropinirole.]
[A04AA03, tropisetron, Tropisetron may increase the sedative activities of Ropinirole.]
[C04AX28, ifenprodil, Ifenprodil may increase the sedative activities of Ropinirole.]
[A10AE04, insulin glargine, The metabolism of Ropinirole can be increased when combined with Insulin glargine.]
[R06AX27, desloratadine, Desloratadine may increase the sedative activities of Ropinirole.]
[N02CC05, almotriptan, Almotriptan may increase the sedative activities of Ropinirole.]
[N05BA10, ketazolam, Ketazolam may increase the sedative activities of Ropinirole.]
[C08CA09, lacidipine, Ropinirole may increase the hypotensive activities of Lacidipine.]
[N03AX09, lamotrigine, Lamotrigine may increase the sedative activities of Ropinirole.]
[S01GX02, levocabastine, Levocabastine may increase the sedative activities of Ropinirole.]
[N07BC04, lofexidine, Lofexidine may increase the sedative activities of Ropinirole.]
[S01AE04, lomefloxacin, The risk or severity of adverse effects can be increased when Lomefloxacin is combined with Ropinirole.]
[N05CD06, lormetazepam, Lormetazepam may increase the sedative activities of Ropinirole.]
[C09AA03, lisinopril, The risk or severity of adverse effects can be increased when Ropinirole is combined with Lisinopril.]
[C08CA11, manidipine, Ropinirole may increase the hypotensive activities of Manidipine.]
[N06AX13, medifoxamine, Medifoxamine may increase the sedative activities of Ropinirole.]
[R06AE03, cyclizine, Cyclizine may increase the sedative activities of Ropinirole.]
[N05CA10, cyclobarbital, Cyclobarbital may increase the sedative activities of Ropinirole.]
[C03DA04, eplerenone, The risk or severity of adverse effects can be increased when Ropinirole is combined with Eplerenone.]
[N05AD03, metylperon, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Melperone.]
[C03AA07, cyclopenthiazide, Ropinirole may increase the hypotensive activities of Cyclopenthiazide.]
[N06AX07, minaprine, Minaprine may increase the sedative activities of Ropinirole.]
[N06AG02, moclobemide, Moclobemide may increase the sedative activities of Ropinirole.]
[N06BA07, modafinil, The metabolism of Ropinirole can be increased when combined with Armodafinil.]
[R06AX02, cyproheptadine, Cyproheptadine may increase the sedative activities of Ropinirole.]
[C09AA13, moexipril, The risk or severity of adverse effects can be increased when Ropinirole is combined with Moexipril.]
[C03XA02, conivaptan, The risk or severity of adverse effects can be increased when Ropinirole is combined with Conivaptan.]
[C02AC05, moxonidine, The risk or severity of adverse effects can be increased when Ropinirole is combined with Moxonidine.]
[G04BE09, vardenafil, The risk or severity of hypotension can be increased when Vardenafil is combined with Ropinirole.]
[M03CA01, dantrolene, Dantrolene may increase the sedative activities of Ropinirole.]
[N06BX04, deanol, Deanol may increase the sedative activities of Ropinirole.]
[C02CC04, debrisoquin, Ropinirole may increase the hypotensive activities of Debrisoquine.]
[A04AD11, nabilone, Nabilone may increase the sedative activities of Ropinirole.]
[N05BA16, nordazepam, Nordazepam may increase the sedative activities of Ropinirole.]
[C07AB12, nebivolol, The risk or severity of adverse effects can be increased when Ropinirole is combined with Nebivolol.]
[N06AX06, nefazodone, Nefazodone may increase the sedative activities of Ropinirole.]
[N05CM16, niaprazine, Niaprazine may increase the sedative activities of Ropinirole.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Ropinirole.]
[N03AG06, tiagabine, Tiagabine may increase the sedative activities of Ropinirole.]
[M03AC11, cisatracurium, Cisatracurium may increase the sedative activities of Ropinirole.]
[R05DA06, normethadone, Normethadone may increase the sedative activities of Ropinirole.]
[N06AB10, escitalopram, Escitalopram may increase the sedative activities of Ropinirole.]
[N06AA01, desipramine, Desipramine may increase the sedative activities of Ropinirole.]
[C09XA02, aliskiren, The risk or severity of adverse effects can be increased when Ropinirole is combined with Aliskiren.]
[N03AF02, oxcarbazepine, Oxcarbazepine may increase the sedative activities of Ropinirole.]
[N06BX07, oxiracetam, Oxiracetam may increase the sedative activities of Ropinirole.]
[L04AB04, adalimumab, The metabolism of Ropinirole can be increased when combined with Adalimumab.]
[R05DA09, dextromethorphan, Dextromethorphan may increase the sedative activities of Ropinirole.]
[N03AC01, paramethadione, Paramethadione may increase the sedative activities of Ropinirole.]
[N02AC01, dextromoramide, Dextromoramide may increase the sedative activities of Ropinirole.]
[N06AB05, paroxetine, Paroxetine may increase the sedative activities of Ropinirole.]
[N07BC06, heroin, Diamorphine may increase the sedative activities of Ropinirole.]
[A03AX15, peppermint oil, The risk or severity of adverse effects can be increased when Peppermint oil is combined with Ropinirole.]
[N05BA01, diazepam, Diazepam may increase the sedative activities of Ropinirole.]
[N03AX07, phenacemide, Phenacemide may increase the sedative activities of Ropinirole.]
[V03AH01, diazoxide, The risk or severity of adverse effects can be increased when Ropinirole is combined with Diazoxide.]
[N03AD02, phensuximide, Phensuximide may increase the sedative activities of Ropinirole.]
[N06AA08, dibenzepin, Dibenzepin may increase the sedative activities of Ropinirole.]
[S02DA04, dibucaine, Cinchocaine may increase the sedative activities of Ropinirole.]
[S01EC02, dichlorphenamide, The risk or severity of adverse effects can be increased when Ropinirole is combined with Diclofenamide.]
[G03CC02, dienestrol, Dienestrol may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.]
[C02DG01, pinacidil, Ropinirole may increase the hypotensive activities of Pinacidil.]
[N05AD05, pipamperone, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Pipamperone.]
[A08AA03, diethylpropion, Diethylpropion may increase the sedative activities of Ropinirole.]
[L02AA01, diethylstilbestrol, Diethylstilbestrol may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA03, isradipine, The risk or severity of adverse effects can be increased when Ropinirole is combined with Isradipine.]
[C02DB01, dihydralazine, The risk or severity of adverse effects can be increased when Dihydralazine is combined with Ropinirole.]
[L02AA02, polyestradiol phosphate, Polyestradiol phosphate may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA01, dihydroergotamine, Dihydroergotamine may increase the sedative activities of Ropinirole.]
[N02AA03, hydromorphone, Hydromorphone may increase the sedative activities of Ropinirole.]
[J05AE08, atazanavir, The risk or severity of adverse effects can be increased when Atazanavir is combined with Ropinirole.]
[B01AC21, treprostinil, Ropinirole may increase the hypotensive activities of Treprostinil.]
[D04AB07, pramoxine, Pramocaine may increase the sedative activities of Ropinirole.]
[C08DB01, diltiazem, The risk or severity of adverse effects can be increased when Ropinirole is combined with Diltiazem.]
[R06AA11, dimenhydrinate, Dimenhydrinate may increase the sedative activities of Ropinirole.]
[M03BX03, pridinol, Pridinol may increase the sedative activities of Ropinirole.]
[N03AG05, progabide, Progabide may increase the sedative activities of Ropinirole.]
[G03CA09, promestriene, Promestriene may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AA02, diphenhydramine, Diphenhydramine may increase the sedative activities of Ropinirole.]
[A07DA01, diphenoxylate, Diphenoxylate may increase the sedative activities of Ropinirole.]
[N05CD10, quazepam, Quazepam may increase the sedative activities of Ropinirole.]
[C09AA06, quinapril, The risk or severity of adverse effects can be increased when Ropinirole is combined with Quinapril.]
[B01AC07, dipyridamole, The risk or severity of adverse effects can be increased when Ropinirole is combined with Dipyridamole.]
[N06BA11, dexmethylphenidate, Dexmethylphenidate may increase the sedative activities of Ropinirole.]
[N06AA23, quinupramine, Quinupramine may increase the sedative activities of Ropinirole.]
[A03FA02, cisapride, Cisapride may increase the sedative activities of Ropinirole.]
[C09AA05, ramipril, The risk or severity of adverse effects can be increased when Ramipril is combined with Ropinirole.]
[N05AL04, remoxipride, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Remoxipride.]
[S02AA12, rifamycin SV, The risk or severity of adverse effects can be increased when Rifamycin is combined with Ropinirole.]
[N07XX02, riluzole, Riluzole may increase the sedative activities of Ropinirole.]
[N05AX08, risperidone, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Risperidone.]
[R06AE09, levocetirizine, Levocetirizine may increase the sedative activities of Ropinirole.]
[N01BB09, ropivacaine, Ropivacaine may increase the sedative activities of Ropinirole.]
[J01MB01, rosoxacin, The risk or severity of adverse effects can be increased when Rosoxacin is combined with Ropinirole.]
[G04BE08, tadalafil, Ropinirole may increase the hypotensive activities of Tadalafil.]
[C02KX02, ambrisentan, Ropinirole may increase the hypotensive activities of Ambrisentan.]
[A03FA03, domperidone, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Domperidone.]
[N06AA16, dothiepin, The risk or severity of adverse effects can be increased when Dosulepin is combined with Ropinirole.]
[N06AA12, doxepin, Doxepin may increase the sedative activities of Ropinirole.]
[R06AA09, doxylamine, Doxylamine may increase the sedative activities of Ropinirole.]
[N06AB06, sertraline, Sertraline may increase the sedative activities of Ropinirole.]
[N01AB08, sevoflurane, Sevoflurane may increase the sedative activities of Ropinirole.]
[N05AD08, droperidol, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Droperidol.]
[A08AA10, sibutramine, Sibutramine may increase the sedative activities of Ropinirole.]
[C09AA11, spirapril, Ropinirole may increase the hypotensive activities of Spirapril.]
[N05AL02, sultopride, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Sultopride.]
[N02CC01, sumatriptan, Sumatriptan may increase the sedative activities of Ropinirole.]
[C07AB13, talinolol, Ropinirole may increase the hypotensive activities of Talinolol.]
[J01MA05, temafloxacin, The risk or severity of adverse effects can be increased when Temafloxacin is combined with Ropinirole.]
[G04CA03, terazosin, The risk or severity of adverse effects can be increased when Ropinirole is combined with Terazosin.]
[M03BX07, tetrazepam, Tetrazepam may increase the sedative activities of Ropinirole.]
[M03BX05, thiocolchicoside, Thiocolchicoside may increase the sedative activities of Ropinirole.]
[N05AB05, thiopropazate, Thiopropazate may increase the sedative activities of Ropinirole.]
[G04BD01, emepronium, Emepronium may increase the sedative activities of Ropinirole.]
[N06AX14, tianeptine, Tianeptine may increase the sedative activities of Ropinirole.]
[G03CX01, tibolone, Tibolone may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.]
[C09AA02, enalapril, The risk or severity of adverse effects can be increased when Ropinirole is combined with Enalapril.]
[N05BA23, tofisopam, Tofisopam may increase the sedative activities of Ropinirole.]
[N06AG03, toloxatone, Toloxatone may increase the sedative activities of Ropinirole.]
[N03AX11, topiramate, Topiramate may increase the sedative activities of Ropinirole.]
[C03CA04, torsemide, The risk or severity of adverse effects can be increased when Torasemide is combined with Ropinirole.]
[C09AA10, trandolapril, The risk or severity of adverse effects can be increased when Ropinirole is combined with Trandolapril.]
[N05CD11, triazulenone, Loprazolam may increase the sedative activities of Ropinirole.]
[N05CC01, chloral hydrate, Chloral hydrate may increase the sedative activities of Ropinirole.]
[N05CM07, triclofos, Triclofos may increase the sedative activities of Ropinirole.]
[R06AA10, trimethobenzamide, Trimethobenzamide may increase the sedative activities of Ropinirole.]
[N01AB04, enflurane, Enflurane may increase the sedative activities of Ropinirole.]
[C02CA06, urapidil, Urapidil may increase the sedative activities of Ropinirole.]
[J01MA04, enoxacin, The risk or severity of adverse effects can be increased when Enoxacin is combined with Ropinirole.]
[N05AL06, veralipride, Veralipride may increase the sedative activities of Ropinirole.]
[S01GX10, epinastine, Epinastine may increase the sedative activities of Ropinirole.]
[N06AX16, venlafaxine, Venlafaxine may increase the sedative activities of Ropinirole.]
[C08CA12, mepirodipine, The risk or severity of adverse effects can be increased when Ropinirole is combined with Barnidipine.]
[C09AA15, zofenopril, Ropinirole may increase the hypotensive activities of Zofenopril.]
[N05CF02, zolpidem, Zolpidem may increase the sedative activities of Ropinirole.]
[N03AX15, zonisamide, Zonisamide may increase the sedative activities of Ropinirole.]
[A10AB06, insulin glulisine, human, The metabolism of Ropinirole can be increased when combined with Insulin glulisine.]
[N05CF01, zopiclone, Zopiclone may increase the sedative activities of Ropinirole.]
[N05AX11, zotepine, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Zotepine.]
[C02AC02, guanfacine, Guanfacine may increase the sedative activities of Ropinirole.]
[B01AC11, iloprost, The risk or severity of adverse effects can be increased when Ropinirole is combined with Iloprost.]
[C01BG01, moricizine, Moricizine may increase the sedative activities of Ropinirole.]
[G02AB03, ergonovine, Ergometrine may increase the sedative activities of Ropinirole.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may increase the sedative activities of Ropinirole.]
[N02CA02, ergotamine, Ergotamine may increase the sedative activities of Ropinirole.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Ropinirole.]
[N05CD04, estazolam, Estazolam may increase the sedative activities of Ropinirole.]
[G03CA03, estradiol, The risk or severity of adverse effects can be increased when Estradiol is combined with Ropinirole.]
[G03CC06, estriol, Estriol may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.]
[G03CA57, estrogens, conjugated (USP), The risk or severity of adverse effects can be increased when Conjugated estrogens is combined with Ropinirole.]
[G03CC04, estrone, Estrone may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.]
[J04AK02, ethambutol, The metabolism of Ropinirole can be decreased when combined with Ethambutol.]
[N05CM08, ethchlorvynol, Ethchlorvynol may increase the sedative activities of Ropinirole.]
[L02AA03, ethinyl estradiol, Ethinylestradiol may increase the excretion rate of Ropinirole which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AF05, amifostine, The risk or severity of adverse effects can be increased when Ropinirole is combined with Amifostine.]
[N03AD01, ethosuximide, Ethosuximide may increase the sedative activities of Ropinirole.]
[N03AB01, ethotoin, Ethotoin may increase the sedative activities of Ropinirole.]
[S01XA06, ethylmorphine, Ethylmorphine may increase the sedative activities of Ropinirole.]
[N01AX07, etomidate, Etomidate may increase the sedative activities of Ropinirole.]
[N05AE03, sertindole, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Sertindole.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Bupropion is combined with Ropinirole.]
[N06AB08, fluvoxamine, The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ropinirole.]
[C01BB03, tocainide, The risk or severity of adverse effects can be increased when Tocainide is combined with Ropinirole.]
[A02BA03, famotidine, The metabolism of Ropinirole can be decreased when combined with Famotidine.]
[P02CA03, albendazole, The metabolism of Ropinirole can be increased when combined with Albendazole.]
[C08CA02, felodipine, The risk or severity of adverse effects can be increased when Ropinirole is combined with Felodipine.]
[N03AX26, fenfluramine, Fenfluramine may increase the sedative activities of Ropinirole.]
[N02AB03, fentanyl, Fentanyl may increase the sedative activities of Ropinirole.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Ropinirole is combined with Clofarabine.]
[N07CA03, flunarizine, Flunarizine may increase the sedative activities of Ropinirole.]
[N05CD03, flunitrazepam, Flunitrazepam may increase the sedative activities of Ropinirole.]
[N06AA14, melitracen, Melitracen may increase the sedative activities of Ropinirole.]
[V03AZ01, ethanol, Ethanol may increase the sedative activities of Ropinirole.]
[N06AB03, fluoxetine, The risk or severity of adverse effects can be increased when Fluoxetine is combined with Ropinirole.]
[N05AF01, flupenthixol, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Flupentixol.]
[N05AB02, fluphenazine, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Fluphenazine.]
[N05CD01, flurazepam, Flurazepam may increase the sedative activities of Ropinirole.]
[N05AG01, fluspirilene, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Fluspirilene.]
[M03AA01, alcuronium, Alcuronium may increase the sedative activities of Ropinirole.]
[G01AX06, furazolidone, Furazolidone may increase the sedative activities of Ropinirole.]
[C03CA01, furosemide, The risk or severity of adverse effects can be increased when Ropinirole is combined with Furosemide.]
[N05CF04, eszopiclone, Eszopiclone may increase the sedative activities of Ropinirole.]
[N05AL05, amisulpride, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Amisulpride.]
[M03AC02, gallamine, Gallamine may increase the sedative activities of Ropinirole.]
[N03AA04, barbexaclone, Barbexaclone may increase the sedative activities of Ropinirole.]
[N06AX08, bifemelane, Bifemelane may increase the sedative activities of Ropinirole.]
[C10AB04, gemfibrozil, The risk or severity of adverse effects can be increased when Gemfibrozil is combined with Ropinirole.]
[N04BC06, cabergoline, Cabergoline may increase the sedative activities of Ropinirole.]
[N03AD03, methsuximide, Methsuximide may increase the sedative activities of Ropinirole.]
[N01AH02, alfentanil, Alfentanil may increase the sedative activities of Ropinirole.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ropinirole.]
[N05CE01, glutethimide, Glutethimide may increase the sedative activities of Ropinirole.]
[C05AE01, nitroglycerin, The risk or severity of adverse effects can be increased when Ropinirole is combined with Nitroglycerin.]
[C02CA04, doxazosin, The risk or severity of adverse effects can be increased when Ropinirole is combined with Doxazosin.]
[C07AB09, esmolol, The risk or severity of adverse effects can be increased when Esmolol is combined with Ropinirole.]
[C09AA09, fosinopril, The risk or severity of adverse effects can be increased when Ropinirole is combined with Fosinopril.]
[D01BA01, griseofulvin, The metabolism of Ropinirole can be increased when combined with Griseofulvin.]
[S01EX01, guanethidine, Ropinirole may increase the hypotensive activities of Guanethidine.]
[N05AD01, haloperidol, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Haloperidol.]
[N01AB01, halothane, Halothane may increase the sedative activities of Ropinirole.]
[N05AH04, quetiapine, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Quetiapine.]
[A10AD05, insulin aspart, human, The metabolism of Ropinirole can be increased when combined with Insulin aspart.]
[N02CX03, iprazochrome, Iprazochrome may increase the sedative activities of Ropinirole.]
[N05CA21, allobarbital, Allobarbital may increase the sedative activities of Ropinirole.]
[C09CA01, losartan, The risk or severity of adverse effects can be increased when Ropinirole is combined with Losartan.]
[N05CA16, hexobarbital, Hexobarbital may increase the sedative activities of Ropinirole.]
[J05AG01, nevirapine, The metabolism of Ropinirole can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The risk or severity of adverse effects can be increased when Ropinirole is combined with Nilvadipine.]
[C09AA04, perindopril, The risk or severity of adverse effects can be increased when Ropinirole is combined with Perindopril.]
[C02DB02, hydralazine, The risk or severity of adverse effects can be increased when Ropinirole is combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, The risk or severity of adverse effects can be increased when Ropinirole is combined with Hydrochlorothiazide.]
[R05DA03, hydrocodone, Hydrocodone may increase the sedative activities of Ropinirole.]
[C03AA02, hydroflumethiazide, The risk or severity of adverse effects can be increased when Ropinirole is combined with Hydroflumethiazide.]
[N05AX07, prothipendyl, Prothipendyl may increase the sedative activities of Ropinirole.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the sedative activities of Ropinirole.]
[C02AC06, rilmenidine, Ropinirole may increase the hypotensive activities of Rilmenidine.]
[H01AC02, somatrem, The metabolism of Ropinirole can be increased when combined with Somatrem.]
[N01AH03, sufentanil, Sufentanil may increase the sedative activities of Ropinirole.]
[N06AA02, imipramine, The risk or severity of adverse effects can be increased when Imipramine is combined with Ropinirole.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Ropinirole is combined with Paclitaxel.]
[M03BX02, tizanidine, Tizanidine may increase the sedative activities of Ropinirole.]
[C03BA11, indapamide, The risk or severity of adverse effects can be increased when Ropinirole is combined with Indapamide.]
[C02CA02, indoramin, The risk or severity of adverse effects can be increased when Ropinirole is combined with Indoramin.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Ropinirole.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Ropinirole.]
[N06AX17, milnacipran, Milnacipran may increase the sedative activities of Ropinirole.]
[N01BB08, articaine, Articaine may increase the sedative activities of Ropinirole.]
[N05BA12, alprazolam, Alprazolam may increase the sedative activities of Ropinirole.]
[N05CH02, ramelteon, Ramelteon may increase the sedative activities of Ropinirole.]
[L01XX35, anagrelide, The risk or severity of adverse effects can be increased when Anagrelide is combined with Ropinirole.]
[C07AA01, alprenolol, Alprenolol may increase the sedative activities of Ropinirole.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Ropinirole.]
[N06AA13, iprindole, Iprindole may increase the sedative activities of Ropinirole.]
[N06AF05, iproniazid, Iproniazid may increase the sedative activities of Ropinirole.]
[N05AA07, chlorproethazine, Chlorproethazine may increase the sedative activities of Ropinirole.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the sedative activities of Ropinirole.]
[C09AA16, imidapril, The risk or severity of adverse effects can be increased when Ropinirole is combined with Imidapril.]
[N01AB06, isoflurane, Isoflurane may increase the sedative activities of Ropinirole.]
[N04BX02, entacapone, Entacapone may increase the sedative activities of Ropinirole.]
[J04AC01, isoniazid, The risk or severity of adverse effects can be increased when Isoniazid is combined with Ropinirole.]
[C01DA14, isosorbide mononitrate, The risk or severity of adverse effects can be increased when Ropinirole is combined with Isosorbide mononitrate.]
[C05AE02, isosorbide dinitrate, The risk or severity of adverse effects can be increased when Ropinirole is combined with Isosorbide dinitrate.]
[C04AA01, isoxsuprine, The risk or severity of adverse effects can be increased when Ropinirole is combined with Isoxsuprine.]
[N06AX18, reboxetine, Reboxetine may increase the sedative activities of Ropinirole.]
[H01AC01, somatropin, The metabolism of Ropinirole can be increased when combined with Somatotropin.]
[L04AC07, tocilizumab, The metabolism of Ropinirole can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, Ketamine may increase the sedative activities of Ropinirole.]
[C02KD01, ketanserin, Ketanserin may increase the sedative activities of Ropinirole.]
[J02AB02, ketoconazole, The risk or severity of adverse effects can be increased when Ketoconazole is combined with Ropinirole.]
[N05AH03, olanzapine, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Olanzapine.]
[V03AC03, deferasirox, The risk or severity of adverse effects can be increased when Deferasirox is combined with Ropinirole.]
[L04AA24, abatacept, The metabolism of Ropinirole can be increased when combined with Abatacept.]
[N04BC09, rotigotine, Rotigotine may increase the sedative activities of Ropinirole.]
[C07AG01, labetalol, The risk or severity of adverse effects can be increased when Ropinirole is combined with Labetalol.]
[C02AA05, deserpidine, Ropinirole may increase the hypotensive activities of Deserpidine.]
[N03AX18, lacosamide, Lacosamide may increase the sedative activities of Ropinirole.]
[C03CC01, ethacrynic acid, The risk or severity of adverse effects can be increased when Ropinirole is combined with Etacrynic acid.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Ropinirole is combined with Levodopa.]
[S02DA01, lidocaine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Ropinirole.]
[N06BA13, armodafinil, The metabolism of Ropinirole can be increased when combined with Armodafinil.]
[C03DB01, amiloride, The risk or severity of adverse effects can be increased when Ropinirole is combined with Amiloride.]
[N02CA07, lisuride, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Lisuride.]
[N06AA07, lofepramine, Lofepramine may increase the sedative activities of Ropinirole.]
[N05BA06, lorazepam, Lorazepam may increase the sedative activities of Ropinirole.]
[N05AH01, loxapine, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Loxapine.]
[V04CC02, magnesium sulfate, Magnesium sulfate may increase the sedative activities of Ropinirole.]
[V04CX04, mannitol, The risk or severity of adverse effects can be increased when Ropinirole is combined with Mannitol.]
[N06AA21, maprotiline, Maprotiline may increase the sedative activities of Ropinirole.]
[A08AA05, mazindol, Mazindol may increase the sedative activities of Ropinirole.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Ropinirole is combined with Mecamylamine.]
[R06AE05, meclizine, Meclizine may increase the sedative activities of Ropinirole.]
[N05BA03, medazepam, Medazepam may increase the sedative activities of Ropinirole.]
[N05CH01, melatonin, Melatonin may increase the sedative activities of Ropinirole.]
[N02AB02, meperidine, Meperidine may increase the sedative activities of Ropinirole.]
[N03AB04, mephenytoin, Mephenytoin may increase the sedative activities of Ropinirole.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the sedative activities of Ropinirole.]
[N01BB03, mepivacaine, Mepivacaine may increase the sedative activities of Ropinirole.]
[N05BC01, meprobamate, Meprobamate may increase the sedative activities of Ropinirole.]
[N02AX05, meptazinol, Meptazinol may increase the sedative activities of Ropinirole.]
[N05AC03, mesoridazine, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Mesoridazine.]
[N05AX13, paliperidone, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Paliperidone.]
[A04AA04, dolasetron, Dolasetron may increase the sedative activities of Ropinirole.]
[N07BC02, methadone, Methadone may increase the sedative activities of Ropinirole.]
[N06BA03, methamphetamine, Metamfetamine may increase the sedative activities of Ropinirole.]
[R06AC05, methapyrilene, Methapyrilene may increase the sedative activities of Ropinirole.]
[N05CM01, methaqualone, Methaqualone may increase the sedative activities of Ropinirole.]
[N03AA30, metharbital, Metharbital may increase the sedative activities of Ropinirole.]
[S01EC05, methazolamide, The risk or severity of adverse effects can be increased when Ropinirole is combined with Methazolamide.]
[G02CB05, metergoline, Metergoline may increase the sedative activities of Ropinirole.]
[H03BB02, methimazole, The risk or severity of adverse effects can be increased when Methimazole is combined with Ropinirole.]
[M03BA03, methocarbamol, Methocarbamol may increase the sedative activities of Ropinirole.]
[N05CA15, methohexital, Methohexital may increase the sedative activities of Ropinirole.]
[N02BG08, ziconotide, Ziconotide may increase the sedative activities of Ropinirole.]
[N05AA02, methotrimeprazine, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Methotrimeprazine.]
[D05BA02, methoxsalen, The risk or severity of adverse effects can be increased when Methoxsalen is combined with Ropinirole.]
[N02BG09, methoxyflurane, Methoxyflurane may increase the sedative activities of Ropinirole.]
[C03AA08, methyclothiazide, The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Ropinirole.]
[C02AB01, methyldopa, The risk or severity of adverse effects can be increased when Ropinirole is combined with Methyldopa.]
[V04CG05, methylene blue, The metabolism of Ropinirole can be increased when combined with Methylene blue.]
[G02AB01, methylergonovine, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Methylergometrine.]
[N06BA04, methylphenidate, The risk or severity of adverse effects can be increased when Methylphenidate is combined with Ropinirole.]
[N03AF03, rufinamide, Rufinamide may increase the sedative activities of Ropinirole.]
[N05CE02, methyprylon, Methyprylon may increase the sedative activities of Ropinirole.]
[N02CA04, methysergide, Methysergide may increase the sedative activities of Ropinirole.]
[A03FA01, metoclopramide, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Metoclopramide.]
[C03BA08, metolazone, The risk or severity of adverse effects can be increased when Ropinirole is combined with Metolazone.]
[C07AB02, metoprolol, The risk or severity of adverse effects can be increased when Metoprolol is combined with Ropinirole.]
[C01BB02, mexiletine, The risk or severity of adverse effects can be increased when Mexiletine is combined with Ropinirole.]
[N06AX03, mianserin, Mianserin may increase the sedative activities of Ropinirole.]
[N05CD08, midazolam, Midazolam may increase the sedative activities of Ropinirole.]
[C09CA03, valsartan, The risk or severity of adverse effects can be increased when Valsartan is combined with Ropinirole.]
[D11AX01, minoxidil, The risk or severity of adverse effects can be increased when Ropinirole is combined with Minoxidil.]
[N05AE02, molindone, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Molindone.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Ropinirole.]
[C01BD01, amiodarone, The risk or severity of adverse effects can be increased when Amiodarone is combined with Ropinirole.]
[N06AA09, amitriptyline, Amitriptyline may increase the sedative activities of Ropinirole.]
[N02AA01, morphine, Morphine may increase the sedative activities of Ropinirole.]
[A04AA05, palonosetron, Palonosetron may increase the sedative activities of Ropinirole.]
[L04AB05, certolizumab pegol, The metabolism of Ropinirole can be increased when combined with Certolizumab pegol.]
[M03AC03, vecuronium, Vecuronium may increase the sedative activities of Ropinirole.]
[N05CA02, amobarbital, Amobarbital may increase the sedative activities of Ropinirole.]
[N06AA17, amoxapine, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Amoxapine.]
[N03AB05, fosphenytoin, The metabolism of Ropinirole can be increased when combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Ropinirole.]
[C07AA12, nadolol, The risk or severity of adverse effects can be increased when Ropinirole is combined with Nadolol.]
[J01MB04, pipemidic acid, The risk or severity of adverse effects can be increased when Pipemidic acid is combined with Ropinirole.]
[N07XX04, sodium oxybate, Sodium oxybate may increase the sedative activities of Ropinirole.]
[J01MB02, nalidixic acid, The risk or severity of adverse effects can be increased when Nalidixic acid is combined with Ropinirole.]
[J01CF06, nafcillin, The metabolism of Ropinirole can be increased when combined with Nafcillin.]
[C04AX21, nafronyl, Naftidrofuryl may increase the sedative activities of Ropinirole.]
[N02AF02, nalbuphine, Nalbuphine may increase the sedative activities of Ropinirole.]
[L04AC03, anakinra, The metabolism of Ropinirole can be increased when combined with Anakinra.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Ropinirole is combined with Duloxetine.]
[N04BX01, tolcapone, Tolcapone may increase the sedative activities of Ropinirole.]
[N01AH06, remifentanil, Remifentanil may increase the sedative activities of Ropinirole.]
[C01CX08, levosimendan, The risk or severity of adverse effects can be increased when Ropinirole is combined with Levosimendan.]
[N05AX14, iloperidone, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Iloperidone.]
[J02AA01, amphotericin B, The risk or severity of adverse effects can be increased when Ropinirole is combined with Amphotericin B.]
[N06AX23, desvenlafaxine, Desvenlafaxine may increase the sedative activities of Ropinirole.]
[C09CA07, telmisartan, The risk or severity of adverse effects can be increased when Ropinirole is combined with Telmisartan.]
[N06AF02, nialamide, Nialamide may increase the sedative activities of Ropinirole.]
[C08CA04, nicardipine, The risk or severity of adverse effects can be increased when Ropinirole is combined with Nicardipine.]
[P02DA01, niclosamide, The risk or severity of adverse effects can be increased when Niclosamide is combined with Ropinirole.]
[C08CA05, nifedipine, The risk or severity of adverse effects can be increased when Nifedipine is combined with Ropinirole.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Ropinirole is combined with Amyl Nitrite.]
[C08CA06, nimodipine, The risk or severity of adverse effects can be increased when Ropinirole is combined with Nimodipine.]
[C08CA07, nisoldipine, The risk or severity of adverse effects can be increased when Ropinirole is combined with Nisoldipine.]
[N05CD02, nitrazepam, Nitrazepam may increase the sedative activities of Ropinirole.]
[C08CA08, nitrendipine, The risk or severity of adverse effects can be increased when Ropinirole is combined with Nitrendipine.]
[R07AX01, nitric oxide, The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Ropinirole.]
[N05CF03, zaleplon, Zaleplon may increase the sedative activities of Ropinirole.]
[N04BC05, pramipexole, The risk or severity of adverse effects can be decreased when Ropinirole is combined with Pramipexole.]
[C02DD01, nitroprusside, The risk or severity of adverse effects can be increased when Ropinirole is combined with Nitroprusside.]
[N01AX13, nitrous oxide, Nitrous oxide may increase the sedative activities of Ropinirole.]
[N06AX04, nomifensine, Nomifensine may increase the sedative activities of Ropinirole.]
[S01AE02, norfloxacin, The risk or severity of adverse effects can be increased when Norfloxacin is combined with Ropinirole.]
[C02KX01, bosentan, Ropinirole may increase the hypotensive activities of Bosentan.]
[N06AA10, nortriptyline, Nortriptyline may increase the sedative activities of Ropinirole.]
[L03AB07, interferon beta-1a, The risk or severity of adverse effects can be increased when Interferon beta-1a is combined with Ropinirole.]
[S02AA16, ofloxacin, The risk or severity of adverse effects can be increased when Ofloxacin is combined with Ropinirole.]
[L04AC04, rilonacept, The metabolism of Ropinirole can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Ropinirole can be increased when combined with Omeprazole.]
[N06AA05, opipramol, Opipramol may increase the sedative activities of Ropinirole.]
[N02AA02, opium, Opium may increase the sedative activities of Ropinirole.]
[G02CB04, quinagolide, The risk or severity of adverse effects can be decreased when Ropinirole is combined with Quinagolide.]
[G04CA02, tamsulosin, The risk or severity of adverse effects can be increased when Ropinirole is combined with Tamsulosin.]
[N05BA04, oxazepam, Oxazepam may increase the sedative activities of Ropinirole.]
[C07AA02, oxprenolol, Oxprenolol may increase the sedative activities of Ropinirole.]
[N02AA05, oxycodone, Oxycodone may increase the sedative activities of Ropinirole.]
[N02AA11, oxymorphone, Oxymorphone may increase the sedative activities of Ropinirole.]
[N05AE01, oxypertine, Oxypertine may increase the sedative activities of Ropinirole.]
[N05AH05, asenapine, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Asenapine.]
[N02AX06, tapentadol, Tapentadol may increase the sedative activities of Ropinirole.]
[M03AC01, pancuronium, Pancuronium may increase the sedative activities of Ropinirole.]
[G04BE02, papaverine, The risk or severity of adverse effects can be increased when Ropinirole is combined with Papaverine.]
[N05CC05, paraldehyde, Paraldehyde may increase the sedative activities of Ropinirole.]
[C02KC01, pargyline, Pargyline may increase the sedative activities of Ropinirole.]
[J01MA03, pefloxacin, The risk or severity of adverse effects can be increased when Pefloxacin is combined with Ropinirole.]
[C07AA23, penbutolol, Penbutolol may increase the sedative activities of Ropinirole.]
[N05AG03, penfluridol, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Penfluridol.]
[N02AD01, pentazocine, Pentazocine may increase the sedative activities of Ropinirole.]
[N05CA01, pentobarbital, Pentobarbital may increase the sedative activities of Ropinirole.]
[N05AB10, perazine, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Perazine.]
[N04BC02, pergolide, Pergolide may increase the sedative activities of Ropinirole.]
[N05AB03, perphenazine, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Perphenazine.]
[N02AD02, phenazocine, Phenazocine may increase the sedative activities of Ropinirole.]
[N06AF03, phenelzine, Phenelzine may increase the sedative activities of Ropinirole.]
[N03AA02, phenobarbital, The metabolism of Ropinirole can be increased when combined with Phenobarbital.]
[N01AH04, phenoperidine, Phenoperidine may increase the sedative activities of Ropinirole.]
[C04AX02, phenoxybenzamine, The risk or severity of adverse effects can be increased when Ropinirole is combined with Phenoxybenzamine.]
[V03AB36, phentolamine, The risk or severity of adverse effects can be increased when Ropinirole is combined with Phentolamine.]
[S01GA05, phenylephrine, The metabolism of Ropinirole can be increased when combined with Phenylephrine.]
[N03AB02, phenytoin, The metabolism of Ropinirole can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Ropinirole can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of adverse effects can be increased when Levofloxacin is combined with Ropinirole.]
[C08CX01, mibefradil, The risk or severity of adverse effects can be increased when Mibefradil is combined with Ropinirole.]
[N05AG02, pimozide, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Pimozide.]
[C07AA03, pindolol, Pindolol may increase the sedative activities of Ropinirole.]
[N05AC04, pipothiazine, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Pipotiazine.]
[C09CA02, eprosartan, The risk or severity of adverse effects can be increased when Ropinirole is combined with Eprosartan.]
[N04BC08, piribedil, The risk or severity of adverse effects can be decreased when Ropinirole is combined with Piribedil.]
[N02AC03, pirinitramide, Piritramide may increase the sedative activities of Ropinirole.]
[J01MA11, grepafloxacin, The risk or severity of adverse effects can be increased when Grepafloxacin is combined with Ropinirole.]
[N02CX01, pizotyline, Pizotifen may increase the sedative activities of Ropinirole.]
[C09CA04, irbesartan, The risk or severity of adverse effects can be increased when Ropinirole is combined with Irbesartan.]
[N05CA22, proxibarbal, Proxibarbal may increase the sedative activities of Ropinirole.]
[A10BG02, rosiglitazone, The risk or severity of adverse effects can be increased when Rosiglitazone is combined with Ropinirole.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Alosetron is combined with Ropinirole.]
[L04AC08, canakinumab, The metabolism of Ropinirole can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, Ropinirole may increase the hypotensive activities of Polythiazide.]
[J05AE03, ritonavir, The metabolism of Ropinirole can be increased when combined with Ritonavir.]
[A10AD04, insulin lispro, The metabolism of Ropinirole can be increased when combined with Insulin lispro.]
[C07AB01, practolol, Ropinirole may increase the hypotensive activities of Practolol.]
[N05BA11, prazepam, Prazepam may increase the sedative activities of Ropinirole.]
[C02CA01, prazosin, The risk or severity of adverse effects can be increased when Ropinirole is combined with Prazosin.]
[N01BB04, prilocaine, Prilocaine may increase the sedative activities of Ropinirole.]
[P01BA03, primaquine, The metabolism of Ropinirole can be increased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Ropinirole can be increased when combined with Primidone.]
[S01HA05, procaine, Procaine may increase the sedative activities of Ropinirole.]
[L01XB01, procarbazine, Procarbazine may increase the sedative activities of Ropinirole.]
[N05AB04, prochlorperazine, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Prochlorperazine.]
[N05AA03, promazine, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Promazine.]
[R06AD02, promethazine, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Promethazine.]
[C01BC03, propafenone, The risk or severity of adverse effects can be increased when Propafenone is combined with Ropinirole.]
[N01AX04, propanidid, Propanidid may increase the sedative activities of Ropinirole.]
[N05AC01, periciazine, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Periciazine.]
[N05CM06, propiomazine, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Propiomazine.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Ropinirole.]
[N02AC04, propoxyphene, Dextropropoxyphene may increase the sedative activities of Ropinirole.]
[C07AA05, propranolol, The risk or severity of adverse effects can be increased when Ropinirole is combined with Propranolol.]
[N02CC04, rizatriptan, Rizatriptan may increase the sedative activities of Ropinirole.]
[B01AC09, epoprostenol, The risk or severity of adverse effects can be increased when Ropinirole is combined with Epoprostenol.]
[R03DC03, montelukast, The metabolism of Ropinirole can be increased when combined with Montelukast.]
[N06AA11, protriptyline, Protriptyline may increase the sedative activities of Ropinirole.]
[N05AX12, aripiprazole, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Aripiprazole.]
[N05CA07, talbutal, Talbutal may increase the sedative activities of Ropinirole.]
[N05CA09, vinbarbital, Vinbarbital may increase the sedative activities of Ropinirole.]
[N05BB02, captodiamine, Captodiame may increase the sedative activities of Ropinirole.]
[M03BA04, styramate, Styramate may increase the sedative activities of Ropinirole.]
[P02CC01, pyrantel, Pyrantel may increase the sedative activities of Ropinirole.]
[R06AC01, pyrilamine, Mepyramine may increase the sedative activities of Ropinirole.]
[C01BA01, quinidine, The risk or severity of adverse effects can be increased when Quinidine is combined with Ropinirole.]
[P01BC01, quinine, Quinine may increase the sedative activities of Ropinirole.]
[A02BA02, ranitidine, The risk or severity of adverse effects can be increased when Ranitidine is combined with Ropinirole.]
[C02AA01, rescinnamine, Ropinirole may increase the hypotensive activities of Rescinnamine.]
[C02AA02, reserpine, Reserpine may increase the sedative activities of Ropinirole.]
[J04AB02, rifampin, The metabolism of Ropinirole can be increased when combined with Rifampicin.]
[N06AX01, 5-hydroxytryptophan, Oxitriptan may increase the sedative activities of Ropinirole.]
[S01FA02, scopolamine, Scopolamine may increase the sedative activities of Ropinirole.]
[N05CA06, secobarbital, The metabolism of Ropinirole can be increased when combined with Secobarbital.]
[N04BD01, selegiline, The risk or severity of adverse effects can be increased when Selegiline is combined with Ropinirole.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Ropinirole is combined with Obinutuzumab.]
[C07AA07, sotalol, The risk or severity of adverse effects can be increased when Ropinirole is combined with Sotalol.]
[C03DA01, spironolactone, The risk or severity of adverse effects can be increased when Ropinirole is combined with Spironolactone.]
